title: Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation.
abstract: Velusetrag (TD-5108) is a potent, selective high intrinsic activity serotonin 5-HT(4) receptor agonist. We assessed effects of Velusetrag on gastrointestinal transit and compared its pharmacokinetics in healthy volunteers (HV) and chronic constipation (CC) patients. Sixty HV were randomly assigned, double-blind to placebo, 5, 15, 30 or 50 mg Velusetrag (single and 6-day dosing). Primary endpoints were colonic transit (geometric centre at 24 h, GC24) and ascending colon emptying (ACE) T(1/2) after first dose. Secondary endpoints included gastric emptying (GE) T(1/2) and colonic filling at 6 h (CF6). Single dose Velusetrag significantly accelerated GC24, ACE T(1/2), and CF6; 30 and 50 mg Velusetrag accelerated all three endpoints. With multiple doses, Velusetrag 30 mg accelerated GC24, and overall accelerated GE T(1/2) at 15-50 mg. Pharmacokinetics studies showed dose proportionality in health, and no significant differences between health and chronic constipation with a 15 mg oral dose of Velusetrag. Stimulation of bowel function after15 mg Velusetrag was similar in CC and controls. There were no serious adverse events; notable adverse events were the predictable gastrointestinal effects such as diarrhoea or altered bowel movements. Velusetrag significantly accelerated intestinal and colonic transit after single dosing and accelerated gastric emptying after multiple dosing. Further studies of its potential as a gastrointestinal and colonic prokinetic are warranted.
authors.affiliation: Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Manini
authors.forename: M
authors.initials: M
authors.lastname: Camilleri
authors.forename: M
authors.initials: M
authors.lastname: Goldberg
authors.forename: S
authors.initials: S
authors.lastname: Sweetser
authors.forename: S
authors.initials: S
authors.lastname: McKinzie
authors.forename: D
authors.initials: D
authors.lastname: Burton
authors.forename: S
authors.initials: S
authors.lastname: Wong
authors.forename: M M
authors.initials: MM
authors.lastname: Kitt
authors.forename: Y-P
authors.initials: YP
authors.lastname: Li
authors.forename: A R
authors.initials: AR
authors.lastname: Zinsmeister
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D053961:Azabicyclo Compounds / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003248:Constipation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology; D005772:Gastrointestinal Transit / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000627:therapeutic use; D011247:Pregnancy; D055815:Young Adult
chemical_list: D053961:Azabicyclo Compounds; D005765:Gastrointestinal Agents; D010919:Placebos; C533727:TD-5108
references.citation: Gastroenterology. 1978 Apr;74(4):698-703
references.pmid: 631507
references.citation: Am J Gastroenterol. 2005 Feb;100(2):362-72
references.pmid: 15667494
references.citation: Gut. 1999 May;44(5):682-6
references.pmid: 10205205
references.citation: J Nucl Med. 1997 Nov;38(11):1807-10
references.pmid: 9374360
references.citation: Clin Gastroenterol Hepatol. 2004 Sep;2(9):796-805
references.pmid: 15354280
references.citation: N Engl J Med. 2008 May 29;358(22):2344-54
references.pmid: 18509121
references.citation: Aliment Pharmacol Ther. 2002 Oct;16(10):1781-90
references.pmid: 12269971
references.citation: Gastroenterology. 1993 Oct;105(4):988-98
references.pmid: 8405884
references.citation: Br J Pharmacol. 2009 Jan;156(2):362-76
references.pmid: 19154432
references.citation: Scand J Gastroenterol. 1997 Sep;32(9):920-4
references.pmid: 9299672
references.citation: Dig Dis Sci. 1991 May;36(5):609-15
references.pmid: 2022162
references.citation: Gastroenterology. 2007 Sep;133(3):761-8
references.pmid: 17854590
references.citation: Neurogastroenterol Motil. 2007 Jan;19(1):30-8
references.pmid: 17187586
references.citation: Gastroenterology. 1992 Jul;103(1):36-42
references.pmid: 1612355
references.citation: Gastroenterology. 2001 Feb;120(2):354-60
references.pmid: 11159875
references.citation: Neurogastroenterol Motil. 2005 Dec;17(6):821-6
references.pmid: 16336497
references.citation: Aliment Pharmacol Ther. 2001 Nov;15(11):1745-51
references.pmid: 11683688
references.citation: Mayo Clin Proc. 1990 Nov;65(11):1456-79
references.pmid: 2232900
references.citation: N Engl J Med. 2003 Oct 2;349(14):1360-8
references.pmid: 14523145
references.citation: Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G942-7
references.pmid: 16603730
references.citation: Br J Pharmacol. 2004 Nov;143(5):549-60
references.pmid: 15466450
references.citation: Am J Physiol. 1989 Aug;257(2 Pt 1):G284-90
references.pmid: 2764112